Cancer Molecular Diagnostics Market 2027

The coronavirus (COVID-19) has become the most emerging pathogens of respiratory disease epidemics. To curb the spread of the COVID-19 (coronavirus disease 2019) pandemic, the world has a high demand for diagnostic systems capable of rapid detection and quantification of the novel coronavirus (SARS-CoV-2). Molecular diagnosis of COVID-19 primarily relies on detecting RNA of the SARS-CoV-2 virus, the causative infectious agent of the pandemic.

Molecular diagnostic tools and assays are crucial for clinical diagnosis, public health surveillance, and mitigation strategies to contain the spread of COVID-19. Coronavirus has infected millions of people worldwide, and the number of COVID-19 cases continues to rise. There are critical needs and tremendous opportunities for analytical chemists to collaborate with multidisciplinary scientists, clinicians, public health practitioners, and engineers in a collective effort to achieve a rapid and accurate diagnosis of COVID-19, improve the understanding of SARS-CoV-2 at the molecular level, and contribute to the development of preventive measures, therapeutics, and vaccines.

Several biomedical companies are rising to the challenge and developing COVID-19 diagnostics. Some of these diagnostics have become commercially available for healthcare workers and clinical laboratories in the last few months. However, the diagnostic technologies have specific limitations and reported several false-positive and false-negative cases, especially during the early stages of infection.

The cancer molecular diagnostics market, including new tests for COVID-19, reflects the large volume of sales for COVID-19 molecular tests in the U.S. and worldwide. The global demand for COVID tests increased rapidly in 2020. Countries with growing numbers of cases have already been ramping up testing capacity to the maximum growth level. Shortages have hindered labs in the supplies of tests and related products such as nasal swabs, transport media, RNA extraction kits, and personal protective equipment. There are also limits where additional staff and instruments are needed.

The preferred technology for COVID diagnostics is RT-PCR due to its detection of the virus itself with high accuracy, which is also related to the chronology of the illness and its symptoms. Serology tests, which detect antibodies, can be useful for diagnostic purposes during the later phases of the illness. But there have been issues with the quality of serology tests and the debate regarding the need or usefulness of large-scale antibody testing to allow the public to return to work.

However, serology tests are likely to remain necessary in certain situations, for example, in testing healthcare or other frontline workers. Due to the shortages of RT-PCR kits and related products, it has become necessary for many labs and governments to purchase antibody tests simply because the alternative was to have no tests at all. 

The global cancer molecular diagnostics market is impacted due to the COVID-19 pandemic as the increasing number of people affected by COVID-19 has resulted in a reduced testing and diagnosis rate of various cancers such as lung cancer, colorectal, ovarian, breast cancers, and others. Lung cancer has been worst affected due to COVID-19 as the COVID-19 is a respiratory disease. Patients would normally consult their doctor for the signs and symptoms that are potentially mistaken for the novel coronavirus. There is a decrease in the number of samples being received in the laboratories—fewer number biopsies being performed in the hospitals due to the COVID-19 pandemic. Regular screening of cancer patients has witnessed a decrease in the number of regular screenings with the decrease in the number of people having medical appointments and repurposing lab resources toward providing COVID-19 testing. Therefore, there is a decrease in the number of diagnostic tests and specific biomarker tests for cancer. 

According to one of the community hospitals, molecular oncology testing had slumped by 25% due to a rapid increase in the COVID-19 cases.  According to the commercial and public payors, less than 4,000 fewer EGFR tests were performed in March 2020. There was a decrease of 14% in the number of new patients diagnosed with colorectal cancer. There was a decreased number of the RAF test by 9%, MSI/MMR test by 8%, and the RAS test by 6%. The number of new patients diagnosed with breast cancer has witnessed a decrease of 8.4%. The new diagnosis of ovarian cancer has witnessed a decrease of 8.6%. There was a decrease of  14% in the number of new patients diagnosed with acute myeloid leukemia. There was a decreased number of the FLT3 test by 12%, the IDH1 test by 11%, and the IDH2  test by 12%.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com